Editorial Director, Addiction & Recovery · Last reviewed January 2025
Cannabis use disorder (CUD) is the most prevalent illicit drug use disorder in the United States following alcohol use disorder, affecting an estimated 5.9 million Americans in 2021. The landscape of cannabis use has shifted substantially with legalization across many states, and with it, the potency of commercially available cannabis has increased dramatically — average THC concentrations have risen from approximately 4% in the 1990s to over 12% in recent years, with concentrates often exceeding 60–80% THC.
DSM-5 Criteria and the CUD Debate
Cannabis use disorder is diagnosed using the same DSM-5 criteria as other SUDs — impaired control, social impairment, risky use, pharmacological features. A contentious clinical debate surrounds the disorder: many users — and some clinicians — question whether CUD is "real" addiction comparable to alcohol or opioid use disorder. The evidence supports the existence of a genuine CUD with neurobiological features, tolerance, and a withdrawal syndrome, though the severity spectrum is wide and many individuals with CUD function relatively well.
Cannabis and Psychosis: The Evidence
The most clinically significant concern about cannabis use in vulnerable individuals is its association with psychotic disorders. Multiple meta-analyses have found that cannabis use is associated with significantly increased risk for psychosis, with odds ratios typically in the range of 1.5–2.0 for any cannabis use and substantially higher (3–5x) for heavy high-potency cannabis use. The evidence suggests this risk is concentrated in individuals with genetic vulnerability (family history of psychotic disorders) and those who initiate use in adolescence. Cannabis can also precipitate acute psychotic episodes and worsen symptoms in individuals with established schizophrenia.
Cannabis Withdrawal Syndrome
The existence of a clinically significant cannabis withdrawal syndrome is now well-established. DSM-5 includes cannabis withdrawal as a diagnosable condition. Symptoms — emerging 24–72 hours after cessation of heavy use and lasting 1–2 weeks — include irritability, anxiety, sleep disturbance, decreased appetite, restlessness, depressed mood, and physical symptoms including sweating, shakiness, and headaches. While not medically dangerous, withdrawal discomfort drives relapse in motivated individuals attempting to quit.
Treatment
There are no FDA-approved medications for cannabis use disorder. Cognitive Behavioral Therapy, Motivational Enhancement Therapy (MET), and Contingency Management have evidence bases for CUD. MET is particularly well-suited to cannabis use disorder given that many individuals with CUD have ambivalence about the need for change — the MI foundation of MET directly addresses this ambivalence. Combined MET/CBT protocols have shown the strongest evidence in clinical trials.
Related: Schizophrenia & Cannabis · Anxiety & Substance Use · Mental Health Overview